Clinical Trial Update: Pasireotide LAR and Pegvisomant Study in Acromegaly [Phase 4]

View source ↗

Summary

Phase 4 trial update from Erasmus Medical Center evaluating Pasireotide LAR in combination with Pegvisomant for acromegaly; the current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Pasireotide LAR (pasireotide)
• Pegvisomant (pegvisomant)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Acromegaly | Phase 4 | Status: UNKNOWN